Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

A study, which was published in The New England Journal of Medicine, found that tirzepatide (Zepbound) is more effective for ...

Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Zepbound Outperforms Wegovy in Head-to-Head Weight Loss Study MONDAY, May 12, 2025 (HealthDay News) — A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% ...

A new report from health data firm Truveta shows there was 50 per cent increase in American teenagers using the weight-loss drug Wegovy, particularly those living with obesity.

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

Participants who are taking GLP-1 medications and have taken them for at least 3 months are needed for a study on eating behavior.

Excess body weight can raise the risk of certain cancers, leading researchers to wonder whether blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in cancer prevention.